1. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012. 91(3):405–417.
Article
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008. 19(3):411–419.
Article
3. Njue C. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products. Biologicals. 2011. 39(5):266–269.
Article
4. Korea Food & Drug Administration. National Institute of Food and Drug Safety Evaluation. Guidelines on the Evaluation of Biosimilar Products. 2009. Seoul (Korea):
5. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2012.
6. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product (Draft). 2012.
8. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Non-inferiority clinical trials (Draft). 2010. 03.
9. Greene CJ, Morland LA, Durkalski VL, Frueh BC. Noninferiority and equivalence designs: issues and implications for mental health research. J Trauma Stress. 2008. 21(5):433–439.
Article
10. Hwang IK, Morikawa T. Design Issues in Noninferiority/Equivalence Trials. Drug Inf J. 1999. 33(4):1205–1218.
Article
11. United States Government Accountability Office. New drug approval: FDA's consideration of evidence from certain clinical trials. 2010. Washington, DC, USA: United States Government Accountability Office.
12. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Choice of the Non-inferiority margin. EMEA/CPMP/EWP/2158/99. 2005. 07. 27. London (UK):
13. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009. 172(1):137–159.
Article
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986. 7(3):177–188.
Article
15. The Cochrane Collaboration. Higgins J, Green S, editors. 9.5.4 Incorporating heterogeneity into random-effects models. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. 2011. [updated March 2011].